[1
]
From the Julius Center for Health Sciences and Primary Care (M.J.M.B., S.M.H., M.B.,
C.H.W., A.M.M.D., T.J.M.V.) and the Department of Medical Microbiology (M.J.M.B.,
S.M.H., M.B., C.H.W., A.M.M.D., T.J.M.V.), University Medical Center (UMC) Utrecht,
and the Department of Immunology and Infectious Diseases, Wilhelmina Children's Hospital,
UMC Utrecht (A.M.M.D., E.A.M.S.), Utrecht, Research Center Linnaeus Institute, Spaarne
Hospital, Hoofddorp (A.M.M.D.), and Julius Clinical, Zeist (R.L., B.O., N.V., E.C.,
A.S., D.E.G.) - all in the Netherlands; Pfizer Vaccine Clinical Research, Maidenhead,
United Kingdom (C.W., S.G., M.P., A.M., A.M.-H., H.S., T.M., G.C.); Pfizer Vaccine
Clinical Research, Collegeville, PA (S.P., E.A.E.); Pfizer Vaccine Research and Early
Development (M.W.P., K.U.J.) and Pfizer Vaccine Clinical Research (D.A.S., E.A.E.,
W.C.G.), Pearl River, NY; and Pfizer Vaccine Clinical Research, Berlin (B.S.-T.).